Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tobramycin/fosfomycin inhalation

Drug Profile

Tobramycin/fosfomycin inhalation

Alternative Names: Corus 1040; GS 9310/11; Inhaled fosfomycin/tobramycin

Latest Information Update: 24 Feb 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Gilead Sciences
  • Class Aminoglycosides; Antibacterials; Epoxy compounds; Organophosphorus compounds; Phosphonic acids; Small molecules
  • Mechanism of Action Cell wall inhibitors; Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Bronchiectasis; Cystic fibrosis-associated respiratory tract infections

Most Recent Events

  • 19 Feb 2014 Tobramycin/fosfomycin inhalation licensed to CURx Pharmaceuticals worldwide
  • 08 Mar 2010 Gilead Sciences completes a phase II trial in Cystic fibrosis-associated respiratory tract infections in USA
  • 18 Oct 2007 Phase-II clinical trials in Bronchiectasis (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top